NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
0.8556
-0.3244 (-27.49%)
At close: May 28, 2025, 4:00 PM
1.380
+0.524 (61.29%)
Pre-market: May 29, 2025, 5:45 AM EDT
NanoVibronix Revenue
NanoVibronix had revenue of $1.03M in the quarter ending March 31, 2025, with 11.29% growth. This brings the company's revenue in the last twelve months to $2.66M, down -6.60% year-over-year. In the year 2024, NanoVibronix had annual revenue of $2.56M with 12.05% growth.
Revenue (ttm)
$2.66M
Revenue Growth
-6.60%
P/S Ratio
0.12
Revenue / Employee
$85,871
Employees
31
Market Cap
2.21M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.56M | 275.00K | 12.05% |
Dec 31, 2023 | 2.28M | 1.53M | 203.59% |
Dec 31, 2022 | 752.00K | -943.00K | -55.63% |
Dec 31, 2021 | 1.70M | 1.07M | 172.07% |
Dec 31, 2020 | 623.00K | 93.00K | 17.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NAOV News
- 13 hours ago - NanoVibronix Responds to False Post - Business Wire
- 21 hours ago - Major Louisiana Hospital Selects ENvue System for Feeding Tube Procedures - Business Wire
- 12 days ago - NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants - Business Wire
- 13 days ago - NanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants - Business Wire
- 16 days ago - NanoVibronix Announces Results from UroShield™ Case Series - Business Wire
- 6 weeks ago - NanoVibronix Regains Nasdaq Compliance - Business Wire
- 2 months ago - NanoVibronix Announces Renewal and Expansion of Distribution Agreement with Dukehill Healthcare Pty Ltd in Australia - Business Wire
- 2 months ago - Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal - Business Wire